RCS - Genedrive PLC - Department for Business and Trade feature

GenedriveAnnouncement

05/11/2024 11:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241105:nRSE0130La&default-theme=true

RNS Number : 0130L  Genedrive PLC  05 November 2024

genedrive plc

("genedrive" or the "Company")

 

Genedrive featured in UK Government Department for Business and Trade
spotlight on UK genomics

 

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company,
is pleased to announce that it has been featured in the UK Government
Department for Business and Trade ("DBT") publication "UK Genomics Spotlight
2024: Celebrating success and looking ahead"

 

The document is available at
https://eu.eventscloud.com/website/6238/life-sciences/
(https://eu.eventscloud.com/website/6238/life-sciences/) .  The report
highlights the UK's depth and breadth of expertise for export as world leaders
in the field of genomics, as well as opportunities for investing in the UK. It
describes the ecosystem which has enabled the delivery of genomic medicine in
the UK and expertise in various national initiatives and programmes which are
contributing to the genomics landscape of the future.

 

The DBT has produced the Genomics Spotlight 2024 to showcase the UK's
expertise in genomics and latest developments that make the UK a hub for
genomics business and investment, and has worked closely with the NHS,
including NHS England and all three of the devolved nations, as well as
encouraging input from several key organisations and companies in the UK.

 

The document showcases UK capabilities in genomics, with the aim to promote
this sector to markets around the world, to promote UK plc and the healthcare
institutions in place.  It highlights both the export potential of UK
companies, as well as the investment potential across the wider NHS
infrastructure and research institutes, being a reminder of the world leading
genomics capabilities of the UK, from the NHS Genomic Medicine Service, to
world leading institutions and research cohorts, and the ever-expanding
innovation of UK small businesses.

 

Gino Miele, CEO of genedrive plc, said: "We are delighted to be featured in
this spotlight document from the UK Department for Business and Trade on UK
genomics capabilities.  Genedrive are at the forefront of enabling
near-patient pharmacogenetic testing in emergency care paradigms and
recognition in features such as this ultimately facilitate education,
awareness and promotion of our innovative products in both domestic and
international markets."

 

For further details please contact:

 

 genedrive plc                                     +44 (0)161 989 0245
 Gino Miele: CEO / Russ Shaw: CFO

 Peel Hunt LLP (Nominated Adviser and Broker)      +44 (0)20 7418 8900
 James Steel / Patrick Birkholm

 Walbrook PR Ltd (Media & Investor Relations)      +44 (0)20 7933 8780 or genedrive@walbrookpr.com
                                                   (mailto:genedrive@walbrookpr.com)
 Anna Dunphy                                       +44 (0)7876 741 001

 

 

About genedrive plc (http://www.genedriveplc.com)

genedrive plc is a pharmacogenetic testing company developing and
commercialising a low cost, rapid, versatile and simple to use point of need
pharmacogenetic platform for the diagnosis of genetic variants. This helps
clinicians to quickly access key genetic information that will aid them make
the right choices over the right medicine or dosage to use for an effective
treatment, particularly important in time-critical emergency care healthcare
paradigms. Based in the UK, the Company is at the forefront of Point of Care
pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on
how your individual genetics impact a medicines ability to work for you.
Therefore, by using pharmacogenetics, medicine choices can be personalised,
made safer and more effective. The Company has launched its two flagship
products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit,
both developed and validated in collaboration with NHS partners and deployed
on its point of care thermocycler platform. Both tests are single-use
disposable cartridges which are ambient temperature stable, circumventing the
requirement for cold chain logistics. The Directors believe the Genedrive®
MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on
antibiotic use in neonatal intensive care units within 26 minutes, ensuring
vital care is delivered, avoiding adverse effects potentially otherwise
encountered and with no negative impact on the patient care pathway. Its
CYP2C19 ID Kit which has no comparably positioned competitor currently allows
clinicians to make a decision on the use of Clopidogrel in stroke patients in
70 minutes, ensuring that patients who are unlikely to benefit from or suffer
adverse effects from Clopidogrel receive an alternative antiplatelet
therapeutic in a timely manner, ultimately improving outcomes. Both tests have
undergone review by the National Institute for Health and Care Clinical
Excellence ("NICE") and have been recommended for use in the UK NHS.  The
Company has a clear commercial strategy focused on accelerating growth through
maximising in-market sales, geographic and portfolio expansion and strategic
M&A, and operates out of its facilities in Manchester.

 

The Company has a clear commercial strategy focused on accelerating growth
through maximising in-market sales, geographic and portfolio expansion and
strategic M&A, and operates out of its facilities in Manchester.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFEILVLEIIS